| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Depreciation and amortization | NaN | 97 | 364 | 773 |
| Net loss | -5,129 | -5,497 | -3,170 | 469 |
| Amortization of debt discount | 291 | 249 | 190 | 381 |
| Amortization of patents | 61 | 262 | NaN | NaN |
| Depreciation | 289 | NaN | NaN | NaN |
| Amortization of right-of-use asset | 26 | 26 | 37 | 72 |
| Loss on abandoned patents | 98 | NaN | 176 | NaN |
| Write off of inventory | NaN | 0 | 0 | 253 |
| Bad debt expense (recovery) | -1 | 23 | 8 | 9 |
| Loss on abandoned patents | NaN | 559 | NaN | NaN |
| Write off of fixed assets | NaN | 104 | NaN | NaN |
| Non-cash stock-based compensation | 544 | 886 | 488 | 1,391 |
| Foreign currency transaction (gains) losses | -1,228 | 193 | -64 | 9,192 |
| Accounts receivable | -310 | 137 | -303 | -257 |
| Inventories | -723 | 1,293 | 322 | 925 |
| Prepaid expenses and other current assets | -129 | -802 | 908 | -1,897 |
| Other assets | -1 | -2 | NaN | NaN |
| Accounts payable and accrued expenses | 92 | -539 | 193 | -360 |
| Net cash used in operating activities | -1,162 | -4,825 | -2,577 | -4,975 |
| Purchases of property and equipment | 11 | 108 | 17 | 39 |
| Disposals of property and equipment | 26 | 76 | NaN | NaN |
| Payments for patent costs | 61 | 259 | -72 | 140 |
| Net cash used in investing activities | -46 | -291 | 55 | -179 |
| Proceeds from long-term debt | NaN | 2,478 | NaN | NaN |
| Proceeds from rights offering, net of fees incurred | NaN | NaN | 0 | 5,392 |
| Proceeds from rights offering, net | NaN | 5,392 | NaN | NaN |
| Cash for exercise of warrants, net | NaN | 0 | 0 | 1,439 |
| Net cash provided by financing activities | NaN | 2,478 | 0 | 6,831 |
| Effect of exchange rates on cash | -228 | 1,351 | -146 | 285 |
| Net change in cash, cash equivalents, and restricted cash | -1,436 | -1,287 | -2,668 | 1,962 |
| Cash, cash equivalents, and restricted cash at beginning of year | 7,771 | 9,058 | 9,764 | NaN |
| Cash, cash equivalents, and restricted cash - end of period | 6,335 | 7,771 | 9,058 | NaN |
Cytosorbents Corp (CTSO)
Cytosorbents Corp (CTSO)